| REVIEW ARTICLE |
|
| Year : 2020 | Volume
: 4
| Issue : 4 | Page : 173-181 |
|
|
The future of injectable orthobiologic substances for knee osteoarthritis: Options beyond platelet-rich plasma
Sandeep Patel, Karan Jindal, Mandeep S Dhillon
Department of Orthopaedics, Post Graduate Institute of Medical Education and Research, Chandigarh, India
Correspondence Address:
Dr. Karan Jindal
Post Graduate Institute of Medical Education and Research, Chandigarh
India
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/jmsr.jmsr_64_20
|
|
|
The management of young arthritic knee and early grades of osteoarthritis (OA) aims to reduce morbidity and improve the quality of life for which newer modalities are emerging. Orthobiologics have emerged as a viable alternative option as they promote tissue regeneration and could be potential disease-modifying agents. Platelet-rich plasma (PRP) has been promising and is among the frontline treatment options in early OA knee; newer orthobiologic research is progressing beyond this and newer products are being tried. Various combinations of PRP with carriers and growth factor extracts from PRP are some new developments. Additional options beyond PRP include autologous conditioned serum, alpha-2 macroglobulin, adipose tissue derivative, bone marrow aspirate concentrate, and gene therapy. This review aims to shed light on the current literature and future potential of the use of these intra-articular orthobiologics in the 21st century.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
